title: Dose- and time-dependent antiplatelet effects of aspirin.
abstract: Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day for 7 days, and, finally, a single 640 mg dose (cumulative dose 960 mg)--in 15 healthy male volunteers. Platelet aggregability was assessed in whole blood (WB) and platelet rich plasma (PRP). The urinary excretions of stable thromboxane (TxM) and prostacyclin (PGI-M) metabolites, and bleeding time were also measured. Platelet COX inhibition was nearly complete already at 37.5 mg aspirin daily, as evidenced by >98% suppression of serum thromboxane B2 and almost abolished arachidonic acid (AA) induced aggregation in PRP 2-6 h after dosing. Bleeding time was similarly prolonged by all dosages of aspirin. Once daily dosing was associated with considerable recovery of AA induced platelet aggregation in WB after 24 hours, even after 960 mg aspirin. Collagen induced aggregation in WB with normal extracellular calcium levels (hirudin anticoagulated) was inhibited <40% at all dosages. TxM excretion was incompletely suppressed, and increased <24 hours after the cumulative 960 mg dose. Aspirin treatment reduced PGI-M already at the lowest dosage (by approximately 25%), but PGI-M excretion and platelet aggregability were not correlated. Antiplatelet effects of aspirin are limited in WB with normal calcium levels. Since recovery of COX-dependent platelet aggregation occurred within 24 hours, once daily dosing of aspirin might be insufficient in patients with increased platelet turnover.
authors.affiliation: Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna), SE-171 76 Stockholm, Sweden.
authors.forename: Christina
authors.initials: C
authors.lastname: Perneby
authors.forename: N Håkan
authors.initials: NH
authors.lastname: Wallén
authors.forename: Cathy
authors.initials: C
authors.lastname: Rooney
authors.forename: Desmond
authors.initials: D
authors.lastname: Fitzgerald
authors.forename: Paul
authors.initials: P
authors.lastname: Hjemdahl
mesh_terms: D000328:Adult; D016718:Arachidonic Acid / Q000378:metabolism; D001241:Aspirin / Q000008:administration & dosage* / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000378:metabolism; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000097:blood; D013931:Thromboxanes / Q000378:metabolism; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D013931:Thromboxanes; D016718:Arachidonic Acid; D013929:Thromboxane B2; D011464:Epoprostenol; D001241:Aspirin